Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095345573> ?p ?o ?g. }
- W2095345573 endingPage "521" @default.
- W2095345573 startingPage "513" @default.
- W2095345573 abstract "In Brief Purpose: To evaluate the efficacy of intravitreal injections of ranibizumab for choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy. Methods: Retrospective case series of 24 eyes affected with choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy treated by intravitreal injections of ranibizumab (0.5 mg/0.05 mL). Best-corrected visual acuity, fundus examination, spectral domain optical coherence tomography, fundus autofluorescence, and fluorescein and indocyanine green angiography were performed for the diagnosis of adult-onset foveomacular vitelliform dystrophy and choroidal neovascularization. After initial 3 monthly injections of ranibizumab, patients were followed up monthly and retreated if neovascular activity persisted. Outcome measure was the proportion of patients losing fewer than 3 lines of visual acuity from baseline to 12 months (final visit). Results: At final visit, the mean number of ranibizumab injections was 4.5 ± 1.29. From baseline to final visit, 21 of 24 eyes (87.5%) lost fewer than 3 lines of visual acuity. Mean best-corrected visual acuity did not change significantly from baseline to final visit (0.37 ± 0.2 logarithm of the minimum angle of resolution vs. 0.30 ± 0.25 logarithm of the minimum angle of resolution, respectively; P = 0.115). Mean central macular thickness significantly decreased from baseline to final visit (327 ± 83 μm vs. 260 ± 57 μm, respectively; P = 0.001). Conclusion: In this series, ranibizumab succeeded in stabilizing best-corrected visual acuity in patients with choroidal neovascularization associated with adult-onset foveomacular vitelliform dystrophy. Ranibizumab seems to be a reasonable therapeutic option in this condition. Retrospective review of 24 eyes treated with ranibizumab for choroidal neovascularization and previously diagnosed with adult-onset foveomacular vitelliform dystrophy. After a 1-year follow-up, a mean of 4.5 ranibizumab injections led to stabilization of visual acuity and reduction of central macular thickness." @default.
- W2095345573 created "2016-06-24" @default.
- W2095345573 creator A5008174671 @default.
- W2095345573 creator A5028081204 @default.
- W2095345573 creator A5056753147 @default.
- W2095345573 creator A5061795899 @default.
- W2095345573 creator A5068980379 @default.
- W2095345573 creator A5086662698 @default.
- W2095345573 date "2013-03-01" @default.
- W2095345573 modified "2023-10-18" @default.
- W2095345573 title "RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH ADULT-ONSET FOVEOMACULAR VITELLIFORM DYSTROPHY" @default.
- W2095345573 cites W1481978003 @default.
- W2095345573 cites W1523822136 @default.
- W2095345573 cites W1965267472 @default.
- W2095345573 cites W1969775043 @default.
- W2095345573 cites W1990879074 @default.
- W2095345573 cites W1994160535 @default.
- W2095345573 cites W1997244967 @default.
- W2095345573 cites W2026467343 @default.
- W2095345573 cites W2035218100 @default.
- W2095345573 cites W2042321005 @default.
- W2095345573 cites W2044181799 @default.
- W2095345573 cites W2073010543 @default.
- W2095345573 cites W2075984382 @default.
- W2095345573 cites W2082606620 @default.
- W2095345573 cites W2085712747 @default.
- W2095345573 cites W2091407629 @default.
- W2095345573 cites W2091989599 @default.
- W2095345573 cites W2093006173 @default.
- W2095345573 cites W2124415048 @default.
- W2095345573 cites W2126151020 @default.
- W2095345573 cites W2142281232 @default.
- W2095345573 cites W2155749423 @default.
- W2095345573 cites W2344185484 @default.
- W2095345573 doi "https://doi.org/10.1097/iae.0b013e3182753adb" @default.
- W2095345573 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23400081" @default.
- W2095345573 hasPublicationYear "2013" @default.
- W2095345573 type Work @default.
- W2095345573 sameAs 2095345573 @default.
- W2095345573 citedByCount "34" @default.
- W2095345573 countsByYear W20953455732014 @default.
- W2095345573 countsByYear W20953455732015 @default.
- W2095345573 countsByYear W20953455732016 @default.
- W2095345573 countsByYear W20953455732017 @default.
- W2095345573 countsByYear W20953455732018 @default.
- W2095345573 countsByYear W20953455732019 @default.
- W2095345573 countsByYear W20953455732020 @default.
- W2095345573 countsByYear W20953455732021 @default.
- W2095345573 countsByYear W20953455732022 @default.
- W2095345573 countsByYear W20953455732023 @default.
- W2095345573 crossrefType "journal-article" @default.
- W2095345573 hasAuthorship W2095345573A5008174671 @default.
- W2095345573 hasAuthorship W2095345573A5028081204 @default.
- W2095345573 hasAuthorship W2095345573A5056753147 @default.
- W2095345573 hasAuthorship W2095345573A5061795899 @default.
- W2095345573 hasAuthorship W2095345573A5068980379 @default.
- W2095345573 hasAuthorship W2095345573A5086662698 @default.
- W2095345573 hasConcept C118487528 @default.
- W2095345573 hasConcept C119767625 @default.
- W2095345573 hasConcept C141071460 @default.
- W2095345573 hasConcept C142724271 @default.
- W2095345573 hasConcept C2776391266 @default.
- W2095345573 hasConcept C2776403814 @default.
- W2095345573 hasConcept C2776694085 @default.
- W2095345573 hasConcept C2777017193 @default.
- W2095345573 hasConcept C2777802072 @default.
- W2095345573 hasConcept C2778257484 @default.
- W2095345573 hasConcept C2780248432 @default.
- W2095345573 hasConcept C2780827179 @default.
- W2095345573 hasConcept C2781065829 @default.
- W2095345573 hasConcept C2781100027 @default.
- W2095345573 hasConcept C2781359195 @default.
- W2095345573 hasConcept C71924100 @default.
- W2095345573 hasConceptScore W2095345573C118487528 @default.
- W2095345573 hasConceptScore W2095345573C119767625 @default.
- W2095345573 hasConceptScore W2095345573C141071460 @default.
- W2095345573 hasConceptScore W2095345573C142724271 @default.
- W2095345573 hasConceptScore W2095345573C2776391266 @default.
- W2095345573 hasConceptScore W2095345573C2776403814 @default.
- W2095345573 hasConceptScore W2095345573C2776694085 @default.
- W2095345573 hasConceptScore W2095345573C2777017193 @default.
- W2095345573 hasConceptScore W2095345573C2777802072 @default.
- W2095345573 hasConceptScore W2095345573C2778257484 @default.
- W2095345573 hasConceptScore W2095345573C2780248432 @default.
- W2095345573 hasConceptScore W2095345573C2780827179 @default.
- W2095345573 hasConceptScore W2095345573C2781065829 @default.
- W2095345573 hasConceptScore W2095345573C2781100027 @default.
- W2095345573 hasConceptScore W2095345573C2781359195 @default.
- W2095345573 hasConceptScore W2095345573C71924100 @default.
- W2095345573 hasIssue "3" @default.
- W2095345573 hasLocation W20953455731 @default.
- W2095345573 hasLocation W20953455732 @default.
- W2095345573 hasOpenAccess W2095345573 @default.
- W2095345573 hasPrimaryLocation W20953455731 @default.
- W2095345573 hasRelatedWork W2011764310 @default.
- W2095345573 hasRelatedWork W2095345573 @default.
- W2095345573 hasRelatedWork W2121621777 @default.
- W2095345573 hasRelatedWork W2132172493 @default.